Latest Medical Research News

Nutritional Growth Solutions Ltd has voluntarily suspended trading on the ASX pending a capital raising announcement, signaling a pivotal moment for the pediatric nutrition company.

Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.

Immutep Limited advances its pivotal Phase III lung cancer trial and reports promising results across multiple oncology and autoimmune programs, supported by a solid cash position to fund operations through 2026.

EMVision Medical Devices has secured ethics approvals for two pivotal clinical studies and received a $400,000 milestone payment, marking significant progress toward commercialising its portable First Responder brain scanner.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

Argenica Therapeutics has won up to $1.5 million in non-dilutive government funding to support its late-stage clinical trial of ARG-007, a promising treatment for acute ischaemic stroke.

Proteomics International has published clinical validation results for PromarkerEso, a novel blood test that detects esophageal adenocarcinoma with remarkable accuracy, promising a non-invasive alternative to costly and uncomfortable endoscopy procedures.

Hearts & Minds Investments Limited is reshaping its leadership by appointing seasoned executive Richard Howes as part-time Managing Director, following operational upgrades under outgoing CEO Brett Jollie.

Cleo Diagnostics has completed alpha testing of its ovarian cancer pre-surgical triage assay kits, confirming robust performance and differentiation between benign and malignant disease. The company now moves forward to assay optimisation and manufacturing scale-up, edging closer to FDA submission and commercial launch.

Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.

Hearts and Minds Investments (HM1) has reported a robust 23.6% increase in its investment portfolio over six months, prompting an early announcement of an increased fully franked half-year dividend of 8.0 cents per share.